Straus, S
While both can help manage blood sugar and appetite, they also share similar side effects that can become uncomfortable if not managed carefully
Dosing errors, contamination, and inconsistent potency are documented problems
While the first drug in this class, exenatide (Byetta), was approved by the FDA in 2005, more recent drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) outperform the older drugs in the class and other anti-obesity medications
Furthermore, being obese or overweight is a significant risk factor, even without weight-loss drugs
This method is preferred as it is relatively painless, causes less discomfort or irritation compared to other injection types, and does not require specialized training or equipment